A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma

BACKGROUND: BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary resistance and relapse exist with single-target immunotherapy. Bispecific CARs are proposed to mitigate these limitations. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Heng, Li, Chenggong, Jiang, Huiwen, Zhao, Xinying, Huang, Zhiping, Jin, Dan, Guo, Tao, Kou, Haiming, Liu, Lin, Tang, Lu, Yin, Ping, Wang, Zhihui, Ai, Lisha, Ke, Sha, Xia, Yimeng, Deng, Jun, Chen, Lei, Cai, Li, Sun, Chunyan, Xia, Linghui, Hua, Gaoquan, Hu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501733/
https://www.ncbi.nlm.nih.gov/pubmed/34627333
http://dx.doi.org/10.1186/s13045-021-01170-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501733/
https://www.ncbi.nlm.nih.gov/pubmed/34627333
http://dx.doi.org/10.1186/s13045-021-01170-7

Ejemplares similares